GlassScriptPhysician profile
Scott Robert Heinz
NPI 1194500645
$3,207.83
in general payments reported to CMS, 2019-2025
28 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $237 · 2024: $1,688 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $533.47 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $466.63 | 2023-2025 | |
| Exact Sciences Corporation | $367.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $276.49 | 2024-2025 | |
| Lilly USA, LLC | $242.40 | 2023-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $173.06 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.66 | 2024-2025 | Jardiance, Synjardy |
| Amgen INC. | $131.45 | 2024-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $110.90 | 2023-2025 | |
| Glaxosmithkline, LLC. | $101.63 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $90.87 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $79.00 | 2023-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $63.93 | 2024-2025 | Breztri, Airsupra |
| Abbott Laboratories | $63.53 | 2024-2025 | Freestyle Libre 3, Eterna |
| Corcept Therapeutics | $62.85 | 2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $41.99 | 2025 | Wellbutrin, Aplenzin |
| Amneal Pharmaceuticals LLC | $34.65 | 2023-2025 | Unithroid |
| Vivus LLC | $34.18 | 2023-2024 | Qsymia |
| Sanofi-Aventis U.S. LLC | $24.92 | 2025 | |
| Dexcom, INC. | $24.02 | 2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $23.59 | 2024 | Heplisav-B |
| Xeris Pharmaceuticals, INC. | $22.41 | 2024 | Recorlev |
| Otsuka America Pharmaceutical, INC. | $20.46 | 2023 | Rexulti |
| Medtronic, INC. | $17.76 | 2023 | Intellis Adaptivestim |
| Renalytix Ai, INC. | $16.73 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $16.32 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $15.93 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $13.07 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Heinz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.